FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma

Cancer Research

Volumn 58, Issue 3, 1998, Pages 380-383

  Esche, Clemens ^a   Subbotin, Vladimir M ^b   Maliszewski, Charles ^c   Lotze, Michael T ^a   Shurin, Michael R ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER MODEL; DENDRITIC CELL; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR GROWTH;

ANIMALS; BIOLOGICAL RESPONSE MODIFIERS; DENDRITIC CELLS; DRUG SCREENING ASSAYS, ANTITUMOR; IMMUNITY, CELLULAR; LYMPHOMA, T-CELL; MALE; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; SKIN NEOPLASMS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0032005228     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. El Kassas, H., and Kirkwood, J. Adjuvant application of interferons. Semin. Oncol., 23: 737-743, 1996.
2. Rosnet, O., Marchetto, S., deLapeyriere, O., and Birnbaum, D. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene, 6: 1641-1650, 1991.
3. Matthews, W., Jordan, C. T., Wiegand, G. W., Pardoll, D., and Lemischka, I. R. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell, 65: 1143-1152, 1991.
4. Rosnet, O., Mattei, M. G., Marchetto, S., and Birnbaum, D. Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Genomics, 9: 380-385, 1991.
5. rd ed. San Diego, CA: Academic Press, in press.
6. Lyman, S. D., James, L., Vanden Bos, T., de Vries, P., Brasel, K., Gliniak, B., Hollingsworth, L. T., Picha, K. S., McKenna, H. J., Splett, R. R., Fletcher, F. F., Maraskovsky, E., Farrah, T., Foxworthe, D., Williams, D. E., and Beckmann, M. P. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell, 75: 1157-1167, 1993.
7. Hannum, C., Culpepper, J., Campbell, D., McClanahan, T., Zurawski, S., Bazan, J. F., Kastelein, R., Hudak, S., Wagner, J., Mattson, J., Luh, J., Duda, G., Martina, N., Peterson, D., Menon, S., Shanafelt, A., Muench, M., Keiner, G., Namikawa, R., Rennick, D., Roncarolo, M. G., Zlotnick, A., Rosnet, O., Dubreuil, P., Birnbaum, D., and Lee, F. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature (Lond.), 368: 643-648, 1994.
8. Lyman, S. D., Brasel, K., Rousseau, A. M., and Williams, D. E. The flt3 ligand: a hematopoietic stem cell factor whose activities are distinct from steel factor. Stem Cells. 12: 99-107, 1994.
9. Lyman, S. D., James, L., Escobar, S., Downey, H., de Vries, P., Brasel, K., Stocking, K., Beckmann, M. P., Copeland, N. G., Cleveland, L. S., Jenkins, N. A., Belmont, J. W., and Davison, B. L. Identification of soluble and membrane-bound isoforms of the murine flt3 ligand generated by alternative splicing of mRNAs. Oncogene, 10: 149-157, 1995.
10. Jacobsen, S. E. W., Okkenhaug, C., Myklebust, J., Veiby, O. P., and Lyman, S. D. The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: synergistic interactions with interleukin (IL)-11, IL-12, and other hematopoietic growth factors. J. Exp. Med., 181: 1357-1363, 1995.
11. Maraskovsky, E., Brasel, K., Teepe, M., Roux, E. R., Lyman, S. D., Shortman, K., and McKenna, H. J. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med., 184: 1953-1962, 1996.
12. Shurin, M. R., Pandharipande, P. P., Zorina, T., Haluszczak, C., Subbotin, V. M., Hunter, O., Brumfieid, A., Storkus, W. J., Maraskovsky, E., and Lotze, M. T. FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell. Immunol., 179: 174-184, 1997.
13. Lynch, D. H., Andreasen, A., Maraskovsky, E., Whitmore, J., Miller, R. E., and Schuh, J. C. L. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med., 3: 625-631, 1997.
14. Tanaka, K., Gorelik, E., Watanabe, M., Hozumi, N., and Jay, G. Rejection of B16 melanoma induced by expression of a transfected major histocompatibility complex class I gene. Mol. Cell. Biol., 8: 1857-1861, 1988.
15. Shurin, M. R., Esche, C., and Lotze, M. T. FLT3: Receptor and ligand: biology and potential clinical application. Cytokine Growth Factor Rev., in press, 1998.
16. Shurin, M. R. Dendritic cells presenting antigen. Cancer Immunol. Immunother., 43: 158-164, 1996.
17. Kraal, G., Breel, M., Janse, M., and Bruin, G. Langerhans' cells, veiled cells, and interdigitating cells in the mouse recognized by a monoclonal antibody. J. Exp. Med., 163: 981-997, 1986.
18. Rigel, D. S., Kopf, A. W., and Friedmann, R. J. The risk of malignant melanoma in the United States: are we making an impact? J. Am. Acad. Dermatol., 17: 1050-1053, 1987.